Keytruda monotherapy benefit extended to low PD-L1 expression, though doubts linger

Detailed data from the Phase III KEYNOTE-042 trial showed that Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) given as monotherapy in the first-line setting could be further extended to treat non-small cell lung cancer (NSCLC) patients with PD-L1 expression of at least 1% and spare them from the addition of chemotherapy. However, an exploratory analysis of the data suggest

Read the full 606 word article

User Sign In